Last Word

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pfizer’s Mark Swindell discusses the ­integration of Wyeth’s vaccine business after the acquisition by Pfizer. As President of Vaccines, Mr. Swindell is helping to create a seamless process for melding the former Wyeth specialty business with Pfizer. One of the stated goals for the combined Pfizer is to become a top-tier biotherapeutics company by 2015. The company’s pipeline now includes a total of six vaccines and 27 biologics in development.

Posted in:

Post a Comment

You must be logged in to post a Comment.